Ann: Final Sofdra Labelling Discussions with FDA, page-215

Hey Hank - Can I respectfully suggest you go back and read BOTs presentations or the various broker reports as to how they arrive at the valuation figures using a very typical biotech discounted cashflow approach. There is significant upside with detailed sales forecasts, a de-risked drug with a clear clinical need, and most importantly an experienced and high quality management team who have successfully launched something like 30 products worldwide.

Remember we are targeting (via telehealth alone) approx 6,300,000 patients (BOT assuming a penetration of 2.5% (considered low-med sensitivity)) with a list price per script of $750. Another thing to remember is we are ready to hit the ground running and be commercialised from day 1, with ridiculous revenue forecasts across all high, medium and low uptake scenarios (suggest you read recent BOT figures).

Lets not also forget we have a team with an abundance of experience in M&As, and we have a low cost business model generating good sales figures. We will be ripe for the picking in a sector which has never been more cashed up in the history of biotechs..

Im more curious as to why you are suggesting these valuations are not meeting your expectations?All thoughts are my own and not financial advice.DYOR!